Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$173.00 USD

173.00
994,173

-0.27 (-0.16%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $172.98 -0.02 (-0.01%) 4:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Hold on to Quest Diagnostics Stock Now

by Zacks Equity Research

Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.

Zacks Equity Research

DGX vs. ADUS: Which Stock Is the Better Value Option?

by Zacks Equity Research

DGX vs. ADUS: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Quest Diagnostics (DGX) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sreyoshi Mukherjee headshot

Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch

by Sreyoshi Mukherjee

As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.

Zacks Equity Research

All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy

by Zacks Equity Research

Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Quest Diagnostics' New Acquisitions and Pacts Aid Growth

by Zacks Equity Research

Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.

Sreyoshi Mukherjee headshot

Bright Near-Term Outlook for Medical Info Systems Industry

by Sreyoshi Mukherjee

Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.

Zacks Equity Research

Why Is Quest Diagnostics (DGX) Down 0.2% Since Last Earnings Report?

by Zacks Equity Research

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Value Investors Pick Quest Diagnostics (DGX) Stock?

by Zacks Equity Research

Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

Trina Mukherjee headshot

Outlook for Outpatient and Home Healthcare Industry Looks Bright

by Trina Mukherjee

Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.

Zacks Equity Research

DGX vs. LHCG: Which Stock Is the Better Value Option?

by Zacks Equity Research

DGX vs. LHCG: Which Stock Is the Better Value Option?

Zacks Equity Research

Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates

by Zacks Equity Research

We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.

Zacks Equity Research

Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 2.37% and 0.51%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.

Zacks Equity Research

Earnings Preview: Quest Diagnostics (DGX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sreyoshi Mukherjee headshot

Women Health a Top Priority Now: 3 Stocks to Watch

by Sreyoshi Mukherjee

Women's healthcare gains global importance, investors might want to keep an eye on these stocks.

Zacks Equity Research

DGX vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DGX vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Invest in Quest Diagnostics (DGX) Stock

by Zacks Equity Research

Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.

Zacks Equity Research

LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

by Zacks Equity Research

The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

Zacks Equity Research

DGX vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DGX vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Is Quest Diagnostics (DGX) Up 3% Since Last Earnings Report?

by Zacks Equity Research

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

DGX vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DGX vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Quest Diagnostics (DGX) Jumps: Stock Rises 9.3%

by Zacks Equity Research

Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.

Sweta Jaiswal headshot

Bright Near-Term Outlook for Medical Info Systems Industry

by Sweta Jaiswal

The wave of digital transition is helping players in the Zacks Medical Info Systems industry to open up bountiful opportunities for investors.